| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Applying rapid ‘de-facto’ HTA in resource-limited settings: Experience from Romania
|
Lopert, Ruth
|
|
2013
|
112 |
3 |
p. 202-208
7 p.
|
artikel
|
| 2 |
Beyond tokenistic participation: Using representational artefacts to enable meaningful public participation in health service design
|
Morrison, Cecily
|
|
2013
|
112 |
3 |
p. 179-186
8 p.
|
artikel
|
| 3 |
Budget-makers and health care systems
|
White, Joseph
|
|
2013
|
112 |
3 |
p. 163-171
9 p.
|
artikel
|
| 4 |
Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers
|
Morgan, Steven G.
|
|
2013
|
112 |
3 |
p. 248-254
7 p.
|
artikel
|
| 5 |
contents
|
|
|
2013
|
112 |
3 |
p. CO4-
1 p.
|
artikel
|
| 6 |
Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time
|
Sandmann, Frank G.
|
|
2013
|
112 |
3 |
p. 285-296
12 p.
|
artikel
|
| 7 |
Evidence based policy decisions through a Bayesian approach: The case of a statin appraisal in the Netherlands
|
Woertman, Willem
|
|
2013
|
112 |
3 |
p. 234-240
7 p.
|
artikel
|
| 8 |
Factors that led to the implementation of the efficiency frontier approach in health economic evaluation in Germany: Do not avoid the elephant in the room. Comment on Klingler et al. (Health Policy 109 (2013) 270–280)
|
Sandmann, Frank
|
|
2013
|
112 |
3 |
p. 297-298
2 p.
|
artikel
|
| 9 |
Factors that led to the implementation of the efficiency frontier approach to health economic evaluation in Germany: Let's talk more about the elephant
|
Klingler, Corinna
|
|
2013
|
112 |
3 |
p. 299-300
2 p.
|
artikel
|
| 10 |
How experts are chosen to inform public policy: Can the process be improved?
|
Rowe, Sylvia
|
|
2013
|
112 |
3 |
p. 172-178
7 p.
|
artikel
|
| 11 |
How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand
|
Gleeson, Deborah
|
|
2013
|
112 |
3 |
p. 227-233
7 p.
|
artikel
|
| 12 |
Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries
|
Leopold, Christine
|
|
2013
|
112 |
3 |
p. 209-216
8 p.
|
artikel
|
| 13 |
Multi-tier drugs assessment in a decentralised health care system. The Italian case-study
|
Jommi, Claudio
|
|
2013
|
112 |
3 |
p. 241-247
7 p.
|
artikel
|
| 14 |
Price cuts and drug spending in South Korea: The case of antihyperlipidemic agents
|
Kwon, Hye-Young
|
|
2013
|
112 |
3 |
p. 217-226
10 p.
|
artikel
|
| 15 |
Rational care or rationing care? The case of cervical screening across the United Kingdom
|
Flynn, Hannah
|
|
2013
|
112 |
3 |
p. 197-201
5 p.
|
artikel
|
| 16 |
The public health benefit of medicines: How it has been assessed in France? The principles and results of five years’ experience
|
Maison, Patrick
|
|
2013
|
112 |
3 |
p. 273-284
12 p.
|
artikel
|
| 17 |
Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis
|
Fischer, Katharina E.
|
|
2013
|
112 |
3 |
p. 187-196
10 p.
|
artikel
|
| 18 |
What do Canadians think about physician–pharmaceutical industry interactions?
|
Holbrook, Anne
|
|
2013
|
112 |
3 |
p. 255-263
9 p.
|
artikel
|
| 19 |
Worlds apart? An exploration of prescribing and medicine-taking decisions by patients, GPs and local policy makers
|
Solomon, Josie
|
|
2013
|
112 |
3 |
p. 264-272
9 p.
|
artikel
|
Tijdschrift beschrijving